|
1
|
Adjuvant docetaxel for node-positive breast cancer.
|
N Engl J Med
|
2005
|
8.00
|
|
2
|
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
|
Cancer Res
|
2009
|
2.51
|
|
3
|
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
|
J Clin Oncol
|
2004
|
2.39
|
|
4
|
Dendritic cell infiltration and prognosis of early stage breast cancer.
|
Clin Cancer Res
|
2004
|
2.34
|
|
5
|
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
|
Lancet Oncol
|
2012
|
1.55
|
|
6
|
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
|
Oncologist
|
2010
|
1.52
|
|
7
|
First epidemiological data from the French Trophoblastic Disease Reference Center.
|
Am J Obstet Gynecol
|
2007
|
1.44
|
|
8
|
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.
|
BMC Cancer
|
2012
|
1.40
|
|
9
|
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.
|
PLoS One
|
2007
|
1.29
|
|
10
|
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
|
J Clin Oncol
|
2004
|
1.16
|
|
11
|
Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
|
Clin Breast Cancer
|
2009
|
1.11
|
|
12
|
Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study.
|
Clin Nutr
|
2009
|
0.96
|
|
13
|
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
|
Cancer
|
2006
|
0.89
|
|
14
|
Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity.
|
Am J Obstet Gynecol
|
2009
|
0.88
|
|
15
|
What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence.
|
Gynecol Oncol
|
2006
|
0.85
|
|
16
|
Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization.
|
Bull Cancer
|
2012
|
0.83
|
|
17
|
A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer.
|
Cancer
|
2008
|
0.82
|
|
18
|
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
|
Oncology
|
2011
|
0.81
|
|
19
|
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
|
Breast Cancer Res Treat
|
2007
|
0.81
|
|
20
|
[Standards, Options and Recommendations for the management of invasive cervical cancer patients (non metastastic)].
|
Bull Cancer
|
2003
|
0.80
|
|
21
|
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
|
Bull Cancer
|
2011
|
0.80
|
|
22
|
[Prognostic factors for febrile neutropenia].
|
Bull Cancer
|
2006
|
0.79
|
|
23
|
[Thrombosis and breast cancer: incidence, risk factors, physiopathology and treatment].
|
Bull Cancer
|
2012
|
0.78
|
|
24
|
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
|
Anticancer Drugs
|
2006
|
0.78
|
|
25
|
Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens.
|
Gynecol Oncol
|
2003
|
0.76
|
|
26
|
New developments in treatment of ovarian carcinoma: focus on trabectedin.
|
Cancer Manag Res
|
2010
|
0.75
|
|
27
|
Mechanisms of resistance to endocrine therapies for breast cancer.
|
Horm Mol Biol Clin Investig
|
2012
|
0.75
|
|
28
|
[Neoadjuvant chemotherapy and ovarian cancer].
|
Bull Cancer
|
2006
|
0.75
|
|
29
|
[Cervix cancer and corpus cancer of the uterus].
|
Rev Prat
|
2011
|
0.75
|
|
30
|
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.
|
Breast Cancer Res Treat
|
2010
|
0.75
|
|
31
|
[Are antiangiogenic antibodies universal for solid tumor?].
|
Bull Cancer
|
2007
|
0.75
|
|
32
|
[Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy].
|
Bull Cancer
|
2005
|
0.75
|
|
33
|
First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
|
Bull Cancer
|
2012
|
0.75
|
|
34
|
[Adjuvant therapies: the example of breast cancer].
|
Rev Prat
|
2008
|
0.75
|
|
35
|
[Anemia and chemotherapy].
|
Bull Cancer
|
2003
|
0.75
|
|
36
|
[Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph node].
|
Bull Cancer
|
2012
|
0.75
|
|
37
|
Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy.
|
Tumori
|
2005
|
0.75
|
|
38
|
[Antihormonal therapy in breast cancer and mTOR inhibitors].
|
Bull Cancer
|
2011
|
0.75
|